Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 284

1.

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.

Bastin D, Aitken AS, Pelin A, Pikor LA, Crupi MJF, Huh MS, Bourgeois-Daigneault MC, Bell JC, Ilkow CS.

J Immunother Cancer. 2018 Jun 19;6(1):62. doi: 10.1186/s40425-018-0366-2.

2.

Oncolytic Viruses for Multiple Myeloma Therapy.

Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST.

Cancers (Basel). 2018 Jun 14;10(6). pii: E198. doi: 10.3390/cancers10060198. Review.

3.

Secretome Screening Reveals Fibroblast Growth Factors as Novel Inhibitors of Viral Replication.

van Asten SD, Raaben M, Nota B, Spaapen RM.

J Virol. 2018 Jun 13. pii: JVI.00260-18. doi: 10.1128/JVI.00260-18. [Epub ahead of print]

PMID:
29899088
4.

Rhabdoviruses as vaccine platforms for infectious disease and cancer.

Zemp F, Rajwani J, Mahoney DJ.

Biotechnol Genet Eng Rev. 2018 Apr;34(1):122-138. doi: 10.1080/02648725.2018.1474320. Epub 2018 May 21.

PMID:
29781359
5.

The emerging role of oncolytic virus therapy against cancer.

Russell L, Peng KW.

Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04.

6.

Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Urbiola C, Santer FR, Petersson M, van der Pluijm G, Horninger W, Erlmann P, Wollmann G, Kimpel J, Culig Z, von Laer D.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556. [Epub ahead of print]

PMID:
29696636
7.

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ, Muik A.

Oncotarget. 2018 Jan 12;9(16):12971-12981. doi: 10.18632/oncotarget.24191. eCollection 2018 Feb 27.

8.

Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein.

Nikolic J, Belot L, Raux H, Legrand P, Gaudin Y, A Albertini A.

Nat Commun. 2018 Mar 12;9(1):1029. doi: 10.1038/s41467-018-03432-4.

9.

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.

Kimpel J, Urbiola C, Koske I, Tober R, Banki Z, Wollmann G, von Laer D.

Viruses. 2018 Mar 2;10(3). pii: E108. doi: 10.3390/v10030108.

10.

Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.

Bishnoi S, Tiwari R, Gupta S, Byrareddy SN, Nayak D.

Viruses. 2018 Feb 23;10(2). pii: E90. doi: 10.3390/v10020090. Review.

11.

Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.

Tarasova IA, Tereshkova AV, Lobas AA, Solovyeva EM, Sidorenko AS, Gorshkov V, Kjeldsen F, Bubis JA, Ivanov MV, Ilina IY, Moshkovskii SA, Chumakov PM, Gorshkov MV.

Oncotarget. 2017 Nov 29;9(2):1785-1802. doi: 10.18632/oncotarget.22751. eCollection 2018 Jan 5.

12.

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF.

Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018.

PMID:
29399408
13.

Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.

Tomczyk T, Wróbel G, Chaber R, Siemieniec I, Piasecki E, Krzystek-Korpacka M, Orzechowska BU.

J Innate Immun. 2018;10(2):131-144. doi: 10.1159/000485143. Epub 2018 Jan 6.

14.

Antitumor Memory T-Cells Become Functionally Mature from 30 to 100 days in a Mouse Model of Neoplasia.

Gao Y, Barmada MA, Bergman I.

Anticancer Res. 2018 Jan;38(1):147-157.

PMID:
29277767
15.

Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.

Tezuka K, Okuma K, Kuramitsu M, Matsuoka S, Tanaka R, Tanaka Y, Hamaguchi I.

J Virol. 2018 Jan 30;92(4). pii: e01885-17. doi: 10.1128/JVI.01885-17. Print 2018 Feb 15.

16.

Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.

Naik S, Galyon GD, Jenks NJ, Steele MB, Miller AC, Allstadt SD, Suksanpaisan L, Peng KW, Federspiel MJ, Russell SJ, LeBlanc AK.

Mol Cancer Ther. 2018 Jan;17(1):316-326. doi: 10.1158/1535-7163.MCT-17-0432. Epub 2017 Nov 20.

17.

Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Felt SA, Grdzelishvili VZ.

J Gen Virol. 2017 Nov 16. doi: 10.1099/jgv.0.000980. [Epub ahead of print]

18.

Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.

Balathasan L, Tang VA, Yadollahi B, Brun J, Labelle M, Lefebvre C, Swift SL, Stojdl DF.

Mol Ther Oncolytics. 2017 Sep 15;7:45-56. doi: 10.1016/j.omto.2017.09.004. eCollection 2017 Dec 15.

19.

Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro.

Jiang B, Lun X, Hao X, Wang Y, Yin X, Huang D, He W, Wang Z.

Biomed Pharmacother. 2017 Nov;95:1201-1208. doi: 10.1016/j.biopha.2017.09.030. Epub 2017 Oct 6.

PMID:
28931212
20.

Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses.

Racine T, Kobinger GP, Arts EJ.

AIDS Res Ther. 2017 Sep 12;14(1):55. doi: 10.1186/s12981-017-0179-2. Review.

Supplemental Content

Loading ...
Support Center